Know Cancer

forgot password

Radical Trachelectomy Outcomes in the Treatment of Early Stage Cervical Cancer

18 Years
40 Years
Open (Enrolling)
Cervical Cancer

Thank you

Trial Information

Radical Trachelectomy Outcomes in the Treatment of Early Stage Cervical Cancer

Before Surgery:

If you agree to take part in this study, before you have the abdominal radical trachelectomy
surgery, the following information will be recorded during one of your regular clinic

- Your race and date of birth.

- Your complete medical and surgical history, including the date of your diagnosis and
your diagnosis before surgery.

- Your weight, height, and body mass index.

During and After Surgery:

During and after surgery, the following information will be gathered from your medical
record or you will be asked:

- If there was any blood loss during surgery.

- How long the surgery lasted.

- If there were any complications during the surgery.

- If you needed any blood transfusions.

- What type of instrument was used for preventing or sealing blood loss.

- How long you stayed in the hospital.

- If you experienced any infections within 1 month after surgery.

- If you experienced any complications within 1 month or later than 1 month after

- The length of time it took to recover your bowel and urinary function.

- If you received any treatments for cancer after surgery, such as radiation therapy,
chemotherapy, or hormonal therapy.

Once a year for up to 5 years, you will also be asked the following questions about your
health and fertility, either by mail or during a regular clinic visit:

- What is the status of the disease?

- Did you want to get pregnant in the last year?

- Did you attempt to get pregnant?

- Did you become pregnant? If so, how you became pregnant and the outcome of the
pregnancy? If not how long did you try to become pregnant and did you try any form of
assisted reproduction?


You will complete 4-5 questionnaires at each of the following times:

- Within 2 weeks before your surgery.

- At 4-6 weeks after surgery

- At 6 months after surgery.

- At 1 year after surgery.

- Once a year for the next 4 years.

These questionnaires will ask about your physical health, mental and emotional health, pain,
vitality, social functioning, general health, quality of life, and sexual functioning. It
will take about 15 minutes to complete all 5 questionnaires. If you do not receive your
follow-up care at MD Anderson, the questionnaires will be mailed to you at the above
time-points with a prepaid return envelope. Mailed questionnaires will be returned to the
study chair in an envelope marked CONFIDENTIAL with NO RETURN ADDRESS on the return
envelope. Your name will not appear on the questionnaires or return envelope. Instead, a
code will be used (on the questionnaires only) that will connect the questionnaires with
your medical record. Only the study chair or study coordinator will have access to the code
document. The document is kept in a locked filing cabinet and/or password protected
computer. All responses will be stored in a locked office.

Length of Study:

You will be on study for up to 5 years. If the disease returns, you will be taken off study.

This is an investigational study.

Up to 100 patients will be enrolled in this study. All will be enrolled at MD Anderson.

Inclusion Criteria:

1. Women with histologically confirmed, primary adenocarcinoma, squamous cell carcinoma
or adenosquamous carcinoma of the uterine cervix.

2. Patients with FIGO stage IA1 (with lymph vascular space invasion), IA2, or IB1

3. Patients must be suitable candidates for surgery.

4. Patients who have signed an approved Informed Consent

5. Patients with a prior malignancy allowed if > 3 years previous with no current
evidence of disease

6. Females older than 18 years who are undergoing radical trachelectomy

7. Women must be able to read and write in either Spanish or English

Exclusion Criteria:

1. Any histological type other than adenocarcinoma, squamous cell carcinoma or
adenosquamous carcinoma of the uterine cervix

2. Tumor size greater than 4 cm

3. FIGO stage II-IV disease

4. Patients with a history of pelvic or abdominal radiotherapy

5. Patients who are pregnant

6. Patients with contraindications to surgery

7. Patients with evidence of metastatic disease by conventional imaging studies,
enlarged pelvic or aortic lymph nodes > 2cm; or histologically positive lymph nodes

Type of Study:


Study Design:

Observational Model: Case-Only, Time Perspective: Prospective

Outcome Measure:

Mean scores for the General Health-Related Quality of Life (SF-12)

Outcome Description:

Completed SF-12 questionnaires at baseline and at each follow-up visit (4-6 weeks, 6 months, 1 year, and annually for 4 more years)

Outcome Time Frame:

Follow up visits annually

Safety Issue:


Principal Investigator

Michael M. Frumovitz, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

UT MD Anderson Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

December 2008

Completion Date:

Related Keywords:

  • Cervical Cancer
  • Cervical Cancer
  • Cervix
  • Questionnaire
  • Adenocarcinoma of uterine cervix
  • Squamous cell carcinoma of uterine cervix
  • Adenosquamous carcinoma of uterine cervix
  • Abdominal radical trachelectomy
  • Trachelectomy
  • Quality of life
  • Sexual functioning
  • Uterine Cervical Neoplasms



UT MD Anderson Cancer CenterHouston, Texas  77030